Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

O3099 PERCUTANEOUS REAMING FOLLOWED BY INJECTION OF A MIXTURE OF DEMINERALIZED BONE MATRIX AND AUTOLOGOUS BONE MARROW FOR THE TREATMENT OF SIMPLE BONE CYSTS IN CHILDREN



Abstract

Aim: To assess the efþcacy of percutaneous reaming of simple bone cysts followed by administration of a mixture of autologous bone marrow combined with demineralized bone matrix. Material-methods: 10 patients (7 boys aged 10 years on average and 3 girls aged 12 years on average) with a bone cyst (3 patients at the femur, and 7 at the humerus), were treated with the same surgical technique. The diagnosis was based exclusively on imaging methods (X-ray, CT, MRI) and no biopsy was performed. Under general analgesia and image intensi-þer control the cystic cavity was aspirated. Should ßuid was encountered then a mixture of bone marrow and demineralized bone matrix (DBM) was injected after thorough reaming of the canal proximally and distally. None of the patients required overnight hospital stay. The limb was protected till the patient became asymptomatic. Results: The average follow-up time was 24 months (9–29 months). No perioperative complications were noted. All patients were asymptomatic at the last examination, with normal limb movement. All bone cysts were classiþed from an independent observer, according to the Neer classiþcation, as type I and II. Conclusion: Percutaneous administration of DBM combined with autologous bone marrow after restoring the continuity of the medullary canal with reaming is a simple surgical technique requiring no hospitalization and a short period of immobilization while the clinical and radiological outcome is excellent.

Theses abstracts were prepared by Professor Dr. Frantz Langlais. Correspondence should be addressed to him at EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.